Dupilumab in a 9-Week-Old with Netherton Syndrome Leads to Deep Symptom Control

    November 2024 in “ Journal of Clinical Immunology ”
    Yannik Vollmuth, Narjes Abdulhameed Alelq, Franziska Sattler, Susanne M. Schmidt, Fabian Hauck
    TLDR Dupilumab effectively controls symptoms in infants with Netherton syndrome.
    A case report of a 9-week-old infant with Netherton syndrome (NS) treated with dupilumab off-label demonstrated rapid and sustained resolution of allergic inflammation, deep symptom control, normalization of the skin microbiome, and catch-up in somatic and psychomotor development without adverse drug reactions. Given the high complication rate of NS in early life, the study recommends off-label use of dupilumab immediately after diagnosis.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results